In an exploratory analysis of a predefined subgroup of 502 patients with poor prognosis disease , 332 ( 66 % ) died ( 174 in the standard chemotherapy group and 158 in the bevacizumab group ) , and a significant difference in overall survival was noted between women who received bevacizumab plus chemotherapy and those who received chemotherapy alone ( restricted mean survival time 345 months [ 95 % CI 320-370 ] with standard chemotherapy vs 393 months [ 370-417 ] with bevacizumab ; log-rank p = 003 ) .